Dallah Healthcare (4004) Fundamentals 2026 — P/E 22.7x, Revenue Analysis | SniperIQ
Dallah Healthcare (4004) is a SA-listed Healthcare company in Medical - Care Facilities with a market capitalization of SAR 10.6B, trading at SAR 104.70 on the SAU. This SniperIQ fundamentals page covers Dallah Healthcare's valuation (P/E 22.7x, P/B 2.6x), profitability (net margin 11.0%), revenue (SAR 4.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Dallah Healthcare's market cap?
Dallah Healthcare (4004) has a market capitalization of approximately SAR 10.6B, trading at SAR 104.70 on the SAU. Market cap moves with the live share price.
What is Dallah Healthcare's P/E ratio?
Dallah Healthcare's trailing twelve-month P/E ratio is 22.7x, with a price-to-book (P/B) of 2.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Dallah Healthcare?
Dallah Healthcare runs a net profit margin of 11.0%, a gross margin of 34.4%, and an operating margin of 11.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Dallah Healthcare generate?
Dallah Healthcare reported revenue of SAR 4.1B for fiscal year 2025, with net income of SAR 538M and earnings per share (EPS) of 5.32. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Dallah Healthcare pay a dividend?
Dallah Healthcare offers a trailing dividend yield of about 2.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Dallah Healthcare financially healthy?
Dallah Healthcare carries a debt-to-equity ratio of 0.98x and a current ratio of 1.20x, with a market beta of -0.44. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Dallah Healthcare a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Dallah Healthcare (4004) the key facts are: market cap SAR 10.6B, P/E 22.7x, revenue SAR 4.1B, 52-week range 90-157.3. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Dallah Healthcare's full fundamentals live
Get Dallah Healthcare's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.